Fludarabine

Fludarabine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Colorectal Cancer、Metastatic Pancreatic Cancer、Metastatic Ovarian Cancer、Metastatic Breast Carcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Fludarabine 研究

• Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

  I 期招募中中国NCT06821048

• CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

  I 期 / II 期招募中中国NCT05948033

• NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

  I 期招募中中国NCT05881525

• Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  I 期招募中美国NCT02508038

• A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

  II 期招募中中国NCT05334823

• Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

  I 期招募中中国NCT07093073

• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  II 期招募中美国NCT02133196

• CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus

  I 期招募中South KoreaNCT07855302

• A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors

  I 期招募中中国NCT07250386

• An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

  早期 I 期招募中中国NCT06469190

• Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

  I 期招募中美国NCT06996119

• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  II 期招募中美国NCT02621021

• A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

  早期 I 期招募中中国NCT06756321

• Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

  I 期招募中South KoreaNCT06699771

• High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

  II 期招募中美国NCT06345495

• A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

  I 期招募中中国NCT06898385

• Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

  II 期招募中美国NCT06028828

• A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

  II 期招募中美国NCT06481592

• Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

  I 期 / II 期招募中美国NCT06236139

• Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

  II 期招募中美国NCT04370301

• PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

  I 期 / II 期招募中中国NCT07510828

• A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

  I 期 / II 期招募中美国澳大利亚Puerto RicoNCT06557265

• A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

  I 期招募中中国NCT06043466

• Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

  I 期招募中美国NCT07222735

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。